PEPGEN INC. Operating Cash Flow
PEPGEN INC. (PEPG) reported Operating Cash Flow of -$34.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- PEPGEN INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$15.81M.
- PEPGEN INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$18.43M.
- PEPGEN INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$15.85M.
- PEPGEN INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$19.26M.
- PEPGEN INC. net cash provided by (used in) operating activities for fiscal 2025 was -$81.64M.
- PEPGEN INC. net cash provided by (used in) operating activities for fiscal 2024 was -$82.37M.
- PEPGEN INC. net cash provided by (used in) operating activities for fiscal 2023 was -$69.00M.
- PEPGEN INC. net cash provided by (used in) operating activities for fiscal 2022 was -$59.27M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$15.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$34.23M 10-Q · filed 2026-08-06 | -$50.08M derived: sum of 3 quarters · filed 2026-08-06 | -$69.34M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$18.43M 10-Q · filed 2026-05-12 | -$34.27M derived: sum of 2 quarters · filed 2026-05-12 | -$53.53M derived: sum of 3 quarters · filed 2026-05-12 | -$77.13M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$15.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$35.10M derived: sum of 2 quarters · filed 2026-03-04 | -$58.70M derived: sum of 3 quarters · filed 2026-08-06 | -$81.64M 10-K · filed 2026-03-04 | |
| 2025-09-30 | -$19.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$42.86M derived: sum of 2 quarters · filed 2026-08-06 | -$65.79M 10-Q · filed 2025-11-12 | -$85.27M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$23.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$46.53M 10-Q · filed 2026-08-06 | -$66.01M derived: sum of 3 quarters · filed 2026-08-06 | -$90.02M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$22.93M 10-Q · filed 2026-05-12 | -$42.41M derived: sum of 2 quarters · filed 2026-05-12 | -$66.42M derived: sum of 3 quarters · filed 2026-05-12 | -$82.77M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$19.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$43.49M derived: sum of 2 quarters · filed 2026-03-04 | -$59.84M derived: sum of 3 quarters · filed 2026-03-04 | -$82.37M 10-K · filed 2026-03-04 | |
| 2024-09-30 | -$24.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$40.37M derived: sum of 2 quarters · filed 2025-11-12 | -$62.90M 10-Q · filed 2025-11-12 | -$82.32M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$16.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$38.88M 10-Q · filed 2025-08-07 | -$58.31M derived: sum of 3 quarters · filed 2025-08-07 | -$74.99M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$22.53M 10-Q · filed 2025-05-08 | -$41.96M derived: sum of 2 quarters · filed 2025-05-08 | -$58.64M derived: sum of 3 quarters · filed 2025-05-08 | -$76.11M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$19.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$36.11M derived: sum of 2 quarters · filed 2025-02-24 | -$53.58M derived: sum of 3 quarters · filed 2025-02-24 | -$69.00M 10-K · filed 2025-02-24 | |
| 2023-09-30 | -$16.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$34.15M derived: sum of 2 quarters · filed 2024-11-07 | -$49.57M 10-Q · filed 2024-11-07 | -$62.96M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$17.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$32.89M 10-Q · filed 2024-08-08 | -$33.10M 10-Q · filed 2023-08-08 | -$46.28M derived: sum of 3 quarters · filed 2024-08-08 | -$67.24M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$15.42M 10-Q · filed 2024-05-14 | -$28.81M derived: sum of 2 quarters · filed 2024-05-14 | -$49.78M derived: sum of 3 quarters · filed 2024-05-14 | -$62.41M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$13.39M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | -$34.35M derived: sum of 2 quarters · filed 2024-03-29 | -$46.99M derived: sum of 3 quarters · filed 2024-03-29 | -$59.27M 10-K/A · filed 2024-03-29 | |
| 2022-09-30 | -$20.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$33.61M derived: sum of 2 quarters · filed 2023-11-08 | -$45.88M 10-Q · filed 2023-11-08 | -$51.86M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$12.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$24.91M 10-Q · filed 2023-08-08 | -$30.90M derived: sum of 3 quarters · filed 2023-08-08 | -$38.55M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$12.27M 10-Q · filed 2023-05-11 | -$18.26M derived: sum of 2 quarters · filed 2023-05-11 | -$25.91M derived: sum of 3 quarters · filed 2023-05-11 | -$32.04M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$5.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$13.63M derived: sum of 2 quarters · filed 2023-03-23 | -$19.77M derived: sum of 3 quarters · filed 2023-03-23 | -$22.60M 10-K · filed 2023-03-23 | |
| 2021-09-30 | -$7.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$13.78M derived: sum of 2 quarters · filed 2022-11-10 | -$16.61M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$6.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$8.96M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | -$2.83M 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |